May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Subconjunctival Ranibizumab (Lucentis ®) for Refractory Squamous Carcinoma of the Conjunctiva With Extension Onto the Cornea
Author Affiliations & Notes
  • C. C. Teng
    The New York Eye Cancer Center, New York, New York
    New York University School of Medicine, New York, New York
  • K. J. Chin
    The New York Eye Cancer Center, New York, New York
  • P. T. Finger
    The New York Eye Cancer Center, New York, New York
    The New York Eye and Ear Infirmary, New York, New York
  • Footnotes
    Commercial Relationships  C.C. Teng, None; K.J. Chin, None; P.T. Finger, None.
  • Footnotes
    Support  Genentech, Inc., San Francisco, CA, and The EyeCare Foundation, http://eyecarefoundation.org
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5701. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. C. Teng, K. J. Chin, P. T. Finger; Subconjunctival Ranibizumab (Lucentis ®) for Refractory Squamous Carcinoma of the Conjunctiva With Extension Onto the Cornea. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5701. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate subconjunctival ranibizumab (Lucentis ®) for squamous carcinoma of the conjunctiva (SCC) and cornea.

Methods: : Four consecutive patients with biopsy-proven, diffuse multifocal SCC were enrolled in the study after IRB approval and informed consent were obtained. All patients had previous ocular history of excision, cryotherapy, mitomycin chemotherapy, and interferon chemotherapy, with a subsequent biopsy positive for recurrent SCC. Treatment involved subconjunctival injections of ranibizumab (0.5 mg) every 2 to 4 weeks. Ophthalmic examinations included visual acuity (ETDRS chart), slit lamp examination and photography, dilated ophthalmoscopy and high frequency ultrasonography. Blood pressure and systemic monitoring were performed.

Results: : No adverse ranibizumab-related ocular or systemic side effects have occurred within the first 6 months of therapy. All patients demonstrated improvement or stabilization in tumor size and corneal neovascularization. Visual acuity was noted to improve (n=2) or remain unchanged (n=2) within 6 months of treatment. No SCC growth has been noted during therapy and no patients developed intraocular tumor invasion by high frequency ultrasonography. Unfortunately, there have also been no cases of complete tumor regression.

Conclusions: : This study suggests that subconjunctival ranibizumab was well tolerated and improved or maintained vision at up to 6 months follow up. Evidence of reduction in tumor size and neovascularization suggests that anti-VEGF therapy may have a role in the treatment of malignant squamous carcinoma of the conjunctiva with corneal extension. Further study of ranibizumab for SCC is warranted.

Clinical Trial: : www.clinicaltrials.gov NCT00456495

Keywords: tumors • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • conjunctiva 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×